Abstract. Background: Familial Hypercholesterolemia (FH)is an under-diagnosed condition.Aim: We applied standard laboratory criteria across a large longitudina
Despite the availability of multiple classes of lipoprotein-lowering medications, some high-risk patients have persistent hypercholesterolemia and may require nonpharmacologic therapy. Lipoprotein apheresis (LA) is a…
This special series of Diabetes Core Update is supported by an independent educational grant from Amarin Corp. For more than 30 years, statins have been…
In this special episode titled “Lipids – Beyond Statins and LDL Cholesterol”, our host, Dr. Neil Skolnik will discuss with two expert guests the details…
Users with access to atnyulmc.org should login with their NYU Langone Credentials. Users with access to home.nyu.edu should login with their NYU Credentials. Still have…
Though the reasons aren’t clear, drops in estrogen likely play a significant role in accelerating plaque, says Matthew Budoff.
New indications supported by CLEAR Outcomes trial
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease with the prevalence of approximately 30%.1 The prevalence goes up among specific high-risk populations:…
New indication for patients with obesity or overweight and a history of cardiovascular disease
New indication for patients with obesity or overweight and a history of cardiovascular disease
Author links open overlay panel Christie M. Ballantyne MD a, Anandita Agarwala MD
